Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neurodegenerative diseases

- PMLiVE

MIT researchers develop AI model to detect Parkinson’s from breathing patterns

The tool uses a series of connected algorithms that can assess if someone has PD from their nocturnal breathing

- PMLiVE

Michael J Fox Foundation awards Koneksa second research grant

The grant will be used to evaluate whether digital biomarkers can help to predict the different stages of Parkinson’s disease

- PMLiVE

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment

NRG received a £2.68m Innovative UK award to help fund research into treatments for Parkinson’s disease, motor neurone disease and other neurodegenerative diseases

- PMLiVE

LifeArc partners with UK Dementia Research Institute

Dementia affects around 900,000 people in the UK and this is expected to rise to around 1.6 million by 2040

- PMLiVE

NRG Therapeutics receives £2.68m Innovate UK Award

The funds will be used for research into new treatments for Parkinson’s and motor neurone disease

- PMLiVE

AbbVie submits Parkinson’s disease therapy to FDA

The therapy offers a first-of-its-kind, 24-hour, continuous subcutaneous delivery

- PMLiVE

The Michael J Fox Foundation gives Asceneuron second research grant

Parkinson's disease affects an estimated seven to ten million people worldwide

- PMLiVE

AbbVie ends partnership with BioArctic to develop treatment for Parkinson’s disease

Results supporting phase 2 trials were presented at the International Congress of Parkinson’s Disease and Movement Disorders in September 2021

- PMLiVE

Parkinson’s UK and Domainex announce new collaboration

Parkinson’s Virtual Biotech plans to invest up to £3m in the project

- PMLiVE

SMC approves Parkinson’s disease treatment Ongentys

The once-daily additional oral treatment for patients living with Parkinson’s disease is now accepted for use within NHS Scotland

- PMLiVE

Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease

Researchers identified eight Parkinson’s disease states, with seven outcomes associated with terminal Parkinson’s disease

- PMLiVE

CHMP rejects Kyowa Kirin’s Parkinson’s disease drug

Results of eight main studies of drug were 'inconsistent', according to the CHMP

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links